M&A / Deals Eli Lilly outlays $7.8bn to acquire sleep drug biotech Centessa Pharmaceutical TechnologyWhether the deal reaches its full value hinges on US regulatory milestones for Centessa's lead candidate, cleminorexton.M&A / DealsNeuroscienceRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaceutical Technology Whether the deal reaches its full value hinges on US regulatory milestones for Centessa’s lead candidate, cleminorexton. M&A / DealsNeuroscienceRead full story Post navigation Previous: Symeres and Ambagon collaborate for colorectal cancer moleculesNext: FDA points to liver injury with Amgen’s Tavneos Related Stories M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B pharminent May 13, 2026 M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal pharminent May 12, 2026 M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy pharminent May 12, 2026
